Aischa Niesar, Melanie Lancien, Seohyun Hong, Chloé M. Naasz, Gbolahan Ajibola, Kenneth Maswabi, Maureen Sakoi, Oganne Batlang, Moyo Sikhulile, Terence Mohammed, Comfort Maphorisa, Leah Carrere, Isabelle Roseto, Ciputra Adijaya Hartana, Toong Seng Tan, Ce Gao, Elizabeth M. Parsons, Renee Hua, Molly Pretorius Holme, Shahin Lockman, Kathleen M. Powis, Mary Carrington, Joseph Makhema, Xu G. Yu, Daniel R. Kuritzkes, Roger L. Shapiro, Mathias Lichterfeld
Broadly neutralizing antibodies (bnAbs) are evaluated as possible alternatives to standard antiretroviral treatment (ART) for maintaining control of HIV-1 replication and may enhance immune responses to reduce or control the viral reservoir. However, the immunological and virological effects of bnAbs in infants and children are unknown. We conducted a detailed analysis of proviral reservoir dynamics and antiviral immune responses in a unique group of young children from Botswana who started ART at birth and then stopped standard ART while receiving the bnAbs 10-1074 and VRC01-LS in a subsequent clinical trial. No quantitative changes in frequencies of proviral sequences were observed during bnAb treatment, but selection of genome-intact proviruses in transcriptionally repressive heterochromatin regions occurred in some study participants. Faster viral rebound following standard ART cessation was linked to elevated proportions of KIR2DL1-positive NK cells. In contrast, delayed viral rebound and more limited viral reservoir size were associated with elevated proportions of NKG2A-positive NK cells and with the HLA-B-21M signal peptide polymorphism. HIV-specific T cell responses were low in all study participants and unrelated to viral reservoir sizes or clinical outcomes following ART interruption. These results suggest that, in young children, specific NK cell subsets and KIR-HLA interactions might be linked to HIV-1 rebound kinetics after substitution of standard ART with bnAbs.